Angle: Milestone In Ovarian Cancer Application
Edison | Jul 05, 2017 09:14AM ET
This morning Angle Plc (LON:AGLE) reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and explored Parsortix’s efficacy in triaging women with ovarian masses before surgery ie looking at whether the tumour is benign or malignant to estimate the extent of the necessary surgery. Both studies recruited 200 patients each and reported sensitivity was up to 95%, while specificity was much higher than existing tests. Angle has refrained from releasing further data, as it believes that the diagnostic algorithms (combining Parsortix findings, RNA markers and patient data) that were developed during the trials could be patented.
The next step is for the test to be optimised, as Angle believes some modifications to the analysis technique could improve performance still further. It will then seek to conduct validation studies to get the CE mark and FDA approval. The update on the further strategy is broadly in line with our expectations, although specific timelines for the validation studies are yet to be clarified. Notably, triaging is just part of the potential in ovarian cancer application. Parsortix captures circulating tumour cells and allows gene expression analysis to determine whether the tumour is malignant. The gene expression, however, could eventually also be used to select the most effective drugs. This would be highly desirable with neoadjuvant chemotherapy for example, when the drugs are given before the surgery. In general, gene expression profiling is widely perceived as one of the major tools for personalised medicine in the future.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.